Cargando…
Blood glucose outcomes of anti-retroviral therapy naïve Ugandan people with HIV with pre-diabetes mellitus initiated on dolutegravir for 48 weeks
BACKGROUND: The Uganda ministry of Health recommends frequent blood glucose monitoring for the first six months on dolutegravir, in people with HIV (PWH) having pre-diabetes mellitus (pre-DM). We sought to determine if indeed PWH with pre-diabetes started on dolutegravir had worse blood glucose outc...
Autores principales: | Mulindwa, Frank, Schwarz, Jean-Marc, Brusselaers, Nele, Nabwana, Martin, Bollinger, Robert, Buzibye, Allan, Amutuhaire, Willington, Yendewa, George, Laker, Eva, Kiguba, Ronald, Castelnuovo, Barbara |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10418540/ https://www.ncbi.nlm.nih.gov/pubmed/37577475 http://dx.doi.org/10.21203/rs.3.rs-3154716/v1 |
Ejemplares similares
-
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023) -
Blood glucose trajectories and incidence of diabetes mellitus in Ugandan people living with HIV initiated on dolutegravir
por: Mulindwa, Frank, et al.
Publicado: (2023) -
Dolutegravir use over 48 weeks is not associated with worsening insulin resistance and pancreatic beta cell function in a cohort of HIV-infected Ugandan adults
por: Mulindwa, Frank, et al.
Publicado: (2023) -
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? A case report
por: Mulindwa, Frank, et al.
Publicado: (2023) -
Should dolutegravir always be withheld in people with HIV on dolutegravir with incident diabetes mellitus? a case report
por: Mulindwa, Frank, et al.
Publicado: (2023)